aglatimagene besadenovec

AXP000144.1 · Viral vector gene therapy

Platform
adenovirus (Ad5, E1-deleted, HSV-TK)
Originator
Advantagene
Sponsor
Candel Therapeutics

Names

NameTypeSource
aglatimagene besadenovecpreferred name, INNcurator, ncit
GliAtakbrandncit
ProstAtakbrandncit
Virafirbrandncit
ADV-tk ambiguouscodencit
CAN-2409codencit

Virus

Role
In vivo gene transfer
Family
Adenoviridae
Virus
human adenovirus 5 (NCBI Taxonomy 28285)
Strain
Ad5
Replication
non replicating
Modifications
E1-deleted (replication-defective) adenoviral vector encoding HSV thymidine kinase; given with oral valacyclovir
Transgenes
HSV-TK
Route
intratumoral
Source
evidence

Cross-references

NCI Thesaurus
C73996
FDA UNII
5Z72SSS34W

Approvals

No regulatory approval recorded.

Clinical trials (13)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT07660094Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)RecruitingPhase 32026-06-152031-10-22500Non-squamous, Non-Small Cell Lung Cancer
NCT07332000A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene BesadenovecRecruitingPhase 22025-10-302027-0245Prostate Cancer (Adenocarcinoma); Prostate Cancer Patients Treated by Radiotherapy
NCT04495153CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLCActive not recruitingPhase 22020-10-132024-12-3190Non Small Cell Lung Cancer
NCT03576612GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade GliomasCompletedPhase 12018-02-272023-06-3041Glioma, Malignant
NCT03131037Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung CancerCompletedPhase 12017-05-042021-12-0112Lung Cancer
NCT02768363Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)Active not recruitingPhase 22016-052024-11187Prostate Cancer
NCT02446093Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic AdenocarcinomaUnknownPhase 22015-102025-1254Borderline Resectable Pancreatic Adenocarcinoma
NCT01997190Intrapleural AdV-tk Therapy in Patients With Malignant Pleural EffusionCompletedPhase 12013-102015-1219Breast Cancer; Lung Cancer; Malignant Pleural Effusion; Mesothelioma; Ovarian Cancer
NCT01436968Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate CancerActive not recruitingPhase 32011-092024-08711Prostate Cancer
NCT00634231A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain TumorsCompletedPhase 12010-102015-128Malignant Glioma; Recurrent Ependymoma
NCT00638612AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)CompletedPhase 12008-082013-0527Pancreatic Adenocarcinoma; Pancreatic Cancer
NCT00589875Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant GliomaCompletedPhase 22007-032015-1252Anaplastic Astrocytoma; Glioblastoma Multiforme; High Grade Glioma; Malignant Glioma
NCT00751270Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant GliomasCompletedPhase 12005-112010-0115Anaplastic Astrocytoma; Glioblastoma Multiforme; Malignant Glioma
Unconfirmed matches (5)

Trials that mention one of the names in a weaker way (a code only in the title, a short or ambiguous name). Not counted above.

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditionsMatched by
NCT03541928Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & SurgeryRecruitingPhase 22018-08-022023-0760High-risk Prostate Cancer; Prostate Cancername in intervention: ADV-tk
NCT03313596Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCCUnknownPhase 32013-032019-12180Hepatocellular Carcinomaintervention named: ADV-tk
NCT00870181ADV-TK Improves Outcome of Recurrent High-Grade GliomaCompletedPhase 22008-012011-1247Glioblastoma; Malignant Glioma of Brainname in intervention: ADV-tk
NCT02202564Preliminary Results for the Double-dose Adenovirus-mediated Adjuvant Therapy Improving Outcome of Liver Transplantation in Patients With Advanced Hepatocellular CarcinomaCompletedPhase 22006-102011-1081Hepatocellular Carcinoma; Liver Cancerintervention named: ADV-tk
NCT00300521Liver Transplantation With ADV-TK Gene Therapy Improves Survival in Patients With Advanced Hepatocellular CarcinomaCompletedPhase 22000-0940Hepatocellular Carcinoma; Liver Transplantationname in intervention: ADV-tk

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 42225101Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial.The Lancet. Oncology2026cited by trial NCT01436968
PMID 42805763Prolonged survival after systemic immune reactivation by aglatimagene besadenovec plus valacyclovir in immune checkpoint inhibitor-refractory non-small cell lung cancer.Journal for immunotherapy of cancer2026cited by trial NCT04495153
PMID 40120123A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma.Neuro-oncology2025cited by trial NCT03576612
PMID 33160076Neoadjuvant Gene-Mediated Cytotoxic Immunotherapy for Non-Small-Cell Lung Cancer: Safety and Immunologic Activity.Molecular therapy : the journal of the American Society of Gene Therapy2021cited by trial NCT03131037
PMID 30883662Phase I study of gene-mediated cytotoxic immunotherapy with AdV-tk as adjuvant to surgery and radiation for pediatric malignant glioma and recurrent ependymoma.Neuro-oncology2019cited by trial NCT00634231
PMID 29550074Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion.Molecular therapy : the journal of the American Society of Gene Therapy2018cited by trial NCT01997190
PMID 26843484Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma.Neuro-oncology2016cited by trial NCT00589875
PMID 25795132Gene-mediated cytotoxic immunotherapy as adjuvant to surgery or chemoradiation for pancreatic adenocarcinoma.Cancer immunology, immunotherapy : CII2015cited by trial NCT00638612
PMID 21844505Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2011cited by trial NCT00751270
Unconfirmed matches (1)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

PubMedTitleJournalYearLinked by
PMID 24052127Intraprostatic distribution and long-term follow-up after AdV-tk immunotherapy as neoadjuvant to surgery in patients with prostate cancer.Cancer gene therapy2013name in title: ADV-tk

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 39881590Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy.Cancer research communications2025name in abstract: CAN-2409
PMID 37228396Uncovering transcriptomic landscape alterations of CAN-2409 in in vitro and in vivo glioma models.Frontiers in medicine2023name in title: CAN-2409
PMID 35017150Systemic high-dose dexamethasone treatment may modulate the efficacy of intratumoral viral oncolytic immunotherapy in glioblastoma models.Journal for immunotherapy of cancer2022name in abstract: CAN-2409
PMID 36032633Perturbing DDR signaling enhances cytotoxic effects of local oncolytic virotherapy and modulates the immune environment in glioma.Molecular therapy oncolytics2022name in abstract: CAN-2409
Unconfirmed matches (1)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

PubMedTitleJournalYearLinked by
PMID 37542389Clinical Efficacy and Safety of AdV-tk Gene Therapy for Patients with Cervical Squamous Intraepithelial Lesion: A Prospective Study.Human gene therapy2023name in title: ADV-tk

NIH grants

ProjectTitleOrganisationPIYearsLinked by
P01CA069246Project 3 Gene Mediated Cytotoxic Immmunotherapy for GBMMASSACHUSETTS GENERAL HOSPITALCHIOCCA, E. ANTONIO2017–2021name in abstract: aglatimagene besadenovec
R44CA203336Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and RadiationADVANTAGENE, INCAGUILAR-CORDOVA, ESTUARDO2016–2021name in abstract: aglatimagene besadenovec
R44CA124032Clinical and Immunologic Evaluation of ProstAtak for Prostate CancerADVANTAGENE, INCAGUILAR-CORDOVA, ESTUARDO2007–2013name in title: ProstAtak
Unconfirmed matches (1)

Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.

ProjectTitleOrganisationPIYearsLinked by
R44CA107745Clinical study of AdV-tk radiogene therapy for malignant gliomaADVANTAGENE, INCAGUILAR-CORDOVA, ESTUARDO2004–2009name in title: ADV-tk

Notes

CAN-2409: non-replicating Ad5 carrying herpes simplex virus thymidine kinase, injected into the tumour and followed by oral valacyclovir (the prodrug is a separate agent, not part of the program). Phase 3 in localised prostate cancer (ProstAtak) reported improved disease-free survival; also studied in glioma (GliAtak) and NSCLC. Virafir is a later brand name.

How to cite

aglatimagene besadenovec (AXP000144.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000144.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.